On the Possibility of Using Succinate in Hypoxia Developing in COVID-19

Aim. To provide a rationale for the feasibility of using the succinate-containing drugs to treat hypoxia associated with COVID-19 based on the analysis of experimental and clinical studies.Materials and methods. 84 Russian and international literature sources concerning the pathogenesis of COVID-19...

Full description

Bibliographic Details
Main Authors: Yu. P. Orlov, N. V. Govorova, O. V. Korpacheva, V. V. Afanasyev, I. A. Khilenko
Format: Article
Language:English
Published: Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia 2021-07-01
Series:Общая реаниматология
Subjects:
Online Access:https://www.reanimatology.com/rmt/article/view/2084
_version_ 1797874203345551360
author Yu. P. Orlov
N. V. Govorova
O. V. Korpacheva
V. V. Afanasyev
I. A. Khilenko
author_facet Yu. P. Orlov
N. V. Govorova
O. V. Korpacheva
V. V. Afanasyev
I. A. Khilenko
author_sort Yu. P. Orlov
collection DOAJ
description Aim. To provide a rationale for the feasibility of using the succinate-containing drugs to treat hypoxia associated with COVID-19 based on the analysis of experimental and clinical studies.Materials and methods. 84 Russian and international literature sources concerning the pathogenesis of COVID-19 and the pathogenetic role of succinate in the management of COVID-19 associated hypoxia, oxidative stress and diaphragmatic dysfunction were analyzed. The literature search was performed using Pubmed and ELIBRARY.ru databases.Results. The literature analysis showed that tissue hypoxia, triggering the pathomorphological cascade of events and resulting in multiple organ failure is a central element of COVID-19 pathogenesis. Experimental and clinical studies show the positive impact of tissue hypoxia correction using succinate in both adult patients and children with various conditions associated with acute respiratory failure.Conclusion. The literature data provide a rationale for using succinate-containing drugs in the treatment of severe COVID-19.
first_indexed 2024-04-10T01:27:11Z
format Article
id doaj.art-716e28ddbf624b59ab8f9556d299bb26
institution Directory Open Access Journal
issn 1813-9779
2411-7110
language English
last_indexed 2024-04-10T01:27:11Z
publishDate 2021-07-01
publisher Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, Russia
record_format Article
series Общая реаниматология
spelling doaj.art-716e28ddbf624b59ab8f9556d299bb262023-03-13T09:32:56ZengFederal Research and Clinical Center of Intensive Care Medicine and Rehabilitology, Moscow, RussiaОбщая реаниматология1813-97792411-71102021-07-01173789810.15360/1813-9779-2021-3-78-981798On the Possibility of Using Succinate in Hypoxia Developing in COVID-19Yu. P. Orlov0N. V. Govorova1O. V. Korpacheva2V. V. Afanasyev3I. A. Khilenko4Омский государственный медицинский университетОмский государственный медицинский университетОмский государственный медицинский университетСеверо-Западный государственный медицинский университет им. И. И. МечниковаГородская клиническая больница № 11Aim. To provide a rationale for the feasibility of using the succinate-containing drugs to treat hypoxia associated with COVID-19 based on the analysis of experimental and clinical studies.Materials and methods. 84 Russian and international literature sources concerning the pathogenesis of COVID-19 and the pathogenetic role of succinate in the management of COVID-19 associated hypoxia, oxidative stress and diaphragmatic dysfunction were analyzed. The literature search was performed using Pubmed and ELIBRARY.ru databases.Results. The literature analysis showed that tissue hypoxia, triggering the pathomorphological cascade of events and resulting in multiple organ failure is a central element of COVID-19 pathogenesis. Experimental and clinical studies show the positive impact of tissue hypoxia correction using succinate in both adult patients and children with various conditions associated with acute respiratory failure.Conclusion. The literature data provide a rationale for using succinate-containing drugs in the treatment of severe COVID-19.https://www.reanimatology.com/rmt/article/view/2084covid-19гипоксияокислительный стрессдиафрагмальная дисфункциясукцинаты
spellingShingle Yu. P. Orlov
N. V. Govorova
O. V. Korpacheva
V. V. Afanasyev
I. A. Khilenko
On the Possibility of Using Succinate in Hypoxia Developing in COVID-19
Общая реаниматология
covid-19
гипоксия
окислительный стресс
диафрагмальная дисфункция
сукцинаты
title On the Possibility of Using Succinate in Hypoxia Developing in COVID-19
title_full On the Possibility of Using Succinate in Hypoxia Developing in COVID-19
title_fullStr On the Possibility of Using Succinate in Hypoxia Developing in COVID-19
title_full_unstemmed On the Possibility of Using Succinate in Hypoxia Developing in COVID-19
title_short On the Possibility of Using Succinate in Hypoxia Developing in COVID-19
title_sort on the possibility of using succinate in hypoxia developing in covid 19
topic covid-19
гипоксия
окислительный стресс
диафрагмальная дисфункция
сукцинаты
url https://www.reanimatology.com/rmt/article/view/2084
work_keys_str_mv AT yuporlov onthepossibilityofusingsuccinateinhypoxiadevelopingincovid19
AT nvgovorova onthepossibilityofusingsuccinateinhypoxiadevelopingincovid19
AT ovkorpacheva onthepossibilityofusingsuccinateinhypoxiadevelopingincovid19
AT vvafanasyev onthepossibilityofusingsuccinateinhypoxiadevelopingincovid19
AT iakhilenko onthepossibilityofusingsuccinateinhypoxiadevelopingincovid19